April 17–22, 2026 · San Diego · 2418 items
← MRD / ctDNA / DTP: from detection to treatment decisions
8 people · 8 posts · 4 abstracts
Nivolumab, pembrolizumab and durvalumab sit in this direction not as new drugs, but because perioperative IO trials wrote ctDNA into the stratification.
Phase II single arm study of tremelimumab and durvalumab (MEDI4736) (T300+D) in advanced hepatocellular carcinomas with Child-Pugh-B cirrhosis (STRIDE in CP-B)
Sukeshi Patel Arora, Lorena Fuentes, James Denno, Jennifer Moseley, Brittany M. Altermatt, Elizabeth Diaz, Joshua Ray Smith, Joel Michalek, Lei Zheng
Tertiary lymphoid structure (TLS)-associated immune circuits define response to durvalumab, trastuzumab, and pertuzumab (DTP) in HER2-enriched early breast cancer
Mailin Li, Xen Ping Hoi, Jenying Deng, Junjun Zheng, Rabia Hashmani, Recep Bayraktar, Wei Qian, Jianying Zhou, Jian Guan, Kai Sun, Hanh Mai, Tiffany Sheu, Susan Haley, Mary Schwartz, Sunil Mathur, Stephen T. Wong, Fotis Nikolo, Keith Syson Chan, Polly Niravath, Jenny C. Chang
STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): Final results of the cohort 2 of INFINITY study by GONO GI
Alberto Giovanni Leone, Alessandra Raimondi, Paolo Manca, Sabina Murgioni, Giovanni G. Cardellino, Alessandro Bittoni, Antonia Strippoli, Maria Bencivenga, Federica Palermo, Floriana Nappo, Silvio K. Garattini, Thereasa Rich, Gaia Rebecchi, Roberta Fazio, Camilla Damonte, Margherita Ambrosini, Cecilia Villa, Greta Gronchi, Sara Lonardi, Filippo Pietrantonio
Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC
Fabrice Barlesi, Tibor Csoszi, Renata Duchnowska, Thomas Egenod, Laurent Greillier, Amanda Psyrri, Maurice Perol, Herve Lena, Agnes Boyer-Chammard, Veronia Todary, Julien Viotti, Pascale André, Carine Paturel, Markus Jensen
Infographic to show the cross trial comparisons of 3 phase III perioperative IO trials in MIBC Only one is positive. Why ? I don't know. Looking forward towards full data of 2 negative trials on day 1 #esmo26 @myESMO
Shattering resistance in resectable NSCLC!
#ESMO26 | POP-DURVA – Phase II
#ESMO26 | POP-DURVA In stage I TNBC, the clinical and immunological effects of a single dose of durvalumab without chemo were evaluated (n=71). - pCR: 1.7% - Objective response: 11.6% - Tumor shrinkage: 41.3% - Conversion to an inflamed phenotype: 33% of initially immune-negative tumors. A single dose of immunotherapy induced substantial immune activation, but pathological response was very limited. The main value of this study lies in identifying potential biomarkers of immunotherapy sensitivity rather than demonstrating the efficacy of a chemo-free approach. However, results after only 15 days of treatment cannot establish the efficacy of longer-term monotherapy.
ESMO 2026 | Does immune activation translate into tumor eradication?